| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/08/2003 | EP1272220A1 Formulation for the prevention of cardiovascular disease |
| 01/08/2003 | EP1272219A1 New combination of a betablocker and a cholesterol-lowering agent |
| 01/08/2003 | EP1272218A2 A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| 01/08/2003 | EP1272202A1 Multiple drug resistance reversal agent |
| 01/08/2003 | EP1272201A2 Use of compatible solutes as substances having free radical scavenging properties |
| 01/08/2003 | EP1272200A1 Divided dose therapies with vascular damaging activity |
| 01/08/2003 | EP1272199A1 Combination therapies with vascular damaging activity |
| 01/08/2003 | EP1272198A1 Use of organophosphorous compounds for producing a medicament for treating infections |
| 01/08/2003 | EP1272197A2 Combination of lecithin with ascorbic acid |
| 01/08/2003 | EP1272196A2 Methods of making the 4-n-butylcyclohexanoic and the undecanoic acid esters of (7 alpha,11 beta)-dimethyl-17 beta-hydroxy-4-estren-3-one and their medical use |
| 01/08/2003 | EP1272195A1 Use of fulvestrant in the treatment of resistant breast cancer |
| 01/08/2003 | EP1272194A2 Composition for use in treatment of ocular hypertension and glaucoma |
| 01/08/2003 | EP1272193A2 Synergistic methods and compositions for treating cancer |
| 01/08/2003 | EP1272192A2 A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
| 01/08/2003 | EP1272191A2 An efficacious dosage regimen of galantamine that reduces side effects |
| 01/08/2003 | EP1272190A2 A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease |
| 01/08/2003 | EP1272189A1 Inhibition of cyclooxygenase-2 activity |
| 01/08/2003 | EP1272188A2 Use of egfr tyrosine kinase inhibitors for treating bresta cancer |
| 01/08/2003 | EP1272187A1 Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system |
| 01/08/2003 | EP1272186A1 Therapeutic combinations of antihypertensive and antiangiogenic agents |
| 01/08/2003 | EP1272185A2 Use of quinazoline derivatives as angiogenesis inhibitors |
| 01/08/2003 | EP1272184A2 Pharmaceutical compositions comprising salmeterol and ipratropium |
| 01/08/2003 | EP1272183A1 Methods and compositions useful in enhancing oxygen delivery to cells |
| 01/08/2003 | EP1272182A2 Use of sabcomeline in the treatment of anxiety |
| 01/08/2003 | EP1272181A2 Modified release formulations containing a hypnotic agent |
| 01/08/2003 | EP1272180A1 Concentrated solutions of carvedilol |
| 01/08/2003 | EP1272179A1 Hydrophilic molecular disperse solutions of carvedilol |
| 01/08/2003 | EP1272178A2 Bilirubin or biliverdin degradation fragments |
| 01/08/2003 | EP1272177A1 Method and formulation for treating resistance to antihypertensives and related conditions |
| 01/08/2003 | EP1272176A1 Adamantyl derivatives as anti-cancer agents |
| 01/08/2003 | EP1272175A2 Il-8 receptor antagonists |
| 01/08/2003 | EP1272174A1 Combination product comprising a non-steroidal antiandrogen and an egfr tyrosine kinase inhibitor |
| 01/08/2003 | EP1272173A1 Methods for inhibiting angiogenesis and tumor growth |
| 01/08/2003 | EP1272172A2 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases |
| 01/08/2003 | EP1272171A1 Synergistic compositions containing choline base and succinic acid for insulin resistance and diabetes |
| 01/08/2003 | EP1272170A1 Ocular growth and nicotinic antagonists |
| 01/08/2003 | EP1272169A2 Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia |
| 01/08/2003 | EP1272168A2 Small organic molecule regulators of cell proliferation |
| 01/08/2003 | EP1272167A1 Hydrophilic/lipophilic polymeric matrix dosage formulation |
| 01/08/2003 | EP1272166A2 Pharmaceutical compositions comprising fluvastatin |
| 01/08/2003 | EP1272164A1 Method for stabilising particle size distribution of a powdery active principle dispersed in a liquid and uses thereof |
| 01/08/2003 | EP1272162A1 Stabilized dry powder formulations |
| 01/08/2003 | EP1272161A2 Lipid-based drug delivery systems against parasitic infections |
| 01/08/2003 | EP1272160A2 Lipid-based drug delivery systems for topical application |
| 01/08/2003 | EP1272157A2 Topical micronutrient delivery system and uses thereof |
| 01/08/2003 | EP1272156A1 Use of alcohol dehydrogenase inhibitors for cosmetic treatment of keratinous materials |
| 01/08/2003 | EP1272155A1 Use of natural substances in the production of cosmetic preparations |
| 01/08/2003 | EP1272148A1 Compositions for metabolic protection and repair of lips |
| 01/08/2003 | EP1272059A2 Method of producing oily suspensions of water-soluble vitamins |
| 01/08/2003 | EP1272058A2 Infant formulas containing long-chain polyunsaturated fatty acids and uses thereof |
| 01/08/2003 | EP1272049A1 Method for the fractionation of oil and polar lipid-containing native raw materials using alcohol and centrifugation |
| 01/08/2003 | EP1272048A2 Method for the fractionation of oil and polar lipid-containing native raw materials |
| 01/08/2003 | EP1272035A1 Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics |
| 01/08/2003 | EP1123284B1 Method for the preparation of citalopram |
| 01/08/2003 | EP1123276B1 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them |
| 01/08/2003 | EP1121356B1 3-tetrahydropyridin-4-yl indoles for treatment of psychotic disorders |
| 01/08/2003 | EP1119355B1 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 01/08/2003 | EP1108095A4 Elephant-nosed toilet plunger |
| 01/08/2003 | EP1098651B1 Novel urokinase inhibitors |
| 01/08/2003 | EP1087973B1 Imidazotriazolopyrimidines used as a drug having an adenosine antagonist activity |
| 01/08/2003 | EP1080189A4 Compositions and methods for the synthesis of fatty acids, their derivatives and downstream products |
| 01/08/2003 | EP1077945B1 Isoquinolines as urokinase inhibitors |
| 01/08/2003 | EP1053239B1 Glucocorticoid-selective anti-inflammatory agents |
| 01/08/2003 | EP1023266B1 Process for making diaryl pyridines useful as cox-2 inhibitors |
| 01/08/2003 | EP1021404B1 Azetidinone derivatives for the treatment of hcmv infections |
| 01/08/2003 | EP1021192B1 Dexamethasone gel |
| 01/08/2003 | EP1009439B1 Polymer-platinum compounds |
| 01/08/2003 | EP1001677A4 A novel method for treating epidermal or dermal conditions |
| 01/08/2003 | EP0996439B1 Beta-alkoxyacrylates against malaria |
| 01/08/2003 | EP0984934B1 Novel orally active iron (iii) chelators |
| 01/08/2003 | EP0983294B1 B-ring estratriene diol sulphates |
| 01/08/2003 | EP0981375B1 Pharmaceutical compositions containing plasma protein |
| 01/08/2003 | EP0973515B1 Solid compositions suitable for oral administration comprising an alkanoyl-l-carnitine magnesium citrate |
| 01/08/2003 | EP0966511B1 Washing disinfectant for hygienic and surgical hand disinfection |
| 01/08/2003 | EP0946175B1 USE OF A COMBINATION OF H+, K+ -ATPase INHIBITORS AND GLUCOCORTICOIDS IN THE TREATMENT OF NASAL POLYPS |
| 01/08/2003 | EP0934286B1 3-alkoxyisoxazol-4-yl-substituted 2-amino carboxylic acid compounds |
| 01/08/2003 | EP0915881B1 Pyrroloazepine compounds |
| 01/08/2003 | EP0906107B1 Compositions comprising vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs |
| 01/08/2003 | EP0892795B1 Piperidinylpyramidine derivatives |
| 01/08/2003 | EP0863878B1 Cyclic nitrones and pharmaceutical compositions containing them |
| 01/08/2003 | EP0857056B1 Antiperspirant or deodorant composition with silicone latex |
| 01/08/2003 | EP0853480B1 Use of a thienotriazolodiazepine to increase apolipoprotein a-i levels |
| 01/08/2003 | EP0833649B1 Methods of preventing or treating allergies |
| 01/08/2003 | EP0796107B1 Sunscreen-wound healing composition |
| 01/08/2003 | EP0689437B1 Use of granisetron for the treatment of post-operative nausea and vomiting |
| 01/08/2003 | EP0646012B1 WOUND HEALING AND TREATMENT OF FIBROTIC DISORDERS BY TGFbeta-3 |
| 01/08/2003 | CN1390253A High order nucleic acid based structures |
| 01/08/2003 | CN1390228A Orally active A adenosine receptor agonists |
| 01/08/2003 | CN1390227A Enzyme catalyzed therapeutic activation |
| 01/08/2003 | CN1390222A Imidazole compounds used as phosphodiesterase VII inhibitors |
| 01/08/2003 | CN1390221A Spiro (2H-1-benzopyran-2,4'-piperididine) derivates as glycine transport inhibitors |
| 01/08/2003 | CN1390220A Kinase inhibitors as therapeutic agents |
| 01/08/2003 | CN1390219A Pyrazolopyrimidines as therapeutic agents |
| 01/08/2003 | CN1390218A New active marine alkaloids |
| 01/08/2003 | CN1390217A Bicyclic and tricyclic heteroaromatic compounds |
| 01/08/2003 | CN1390216A Polymorphsof crystalline (2-benzhycrryl-1-azabicyclo [2,2,2] oct-3-YC)-(5-isopropyl-2-methoxybenzyl)-ammoniumchloride as NK-1 receptor antagonists |
| 01/08/2003 | CN1390215A 酪氨酸激酶抑制剂 Tyrosine kinase inhibitor |
| 01/08/2003 | CN1390214A New phenylpiperazines |
| 01/08/2003 | CN1390213A Aryloxy propanolamines for improving livestock production |
| 01/08/2003 | CN1390211A Benzoic ester comprising ethoxyl acyl piperazine substituted oxazolidone compound |